Effect of Alirocumab on Mortality After Acute Coronary Syndromes
An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

ORIGINAL RESEARCH ARTICLE

BACKGROUND: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome.

METHODS: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death.

RESULTS: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P = 0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P = 0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P = 0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P = 0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001 for the associations). A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction =0.007). In the alirocumab group, all-cause death declined with achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P = 0.017 for linear trend).

CONCLUSIONS: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low.

CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402.

Sources of Funding, see page 111

Key Words: acute coronary syndrome ◼ alirocumab ◼ cholesterol ◼ mortality ◼ PCSK9 protein

© 2019 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.

Philippe Gabriel Steg, MD*
Gregory G. Schwartz, MD, PhD* et al
Clinical Perspective

What Is New?

- In a randomized, double-blind trial in 18,924 patients with acute coronary syndrome and elevated atherogenic lipoproteins despite intensive statin treatment, fewer deaths occurred with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor alirocumab (334, 3.5%) than with placebo (392, 4.1%; P=0.03, nominal P value).
- In 8,242 patients eligible for at least 3 years of follow-up, alirocumab reduced mortality (P=0.01).

What Are the Clinical Implications?

- Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndromes, particularly if treatment is maintained for ≥3 years.

METHODS

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Study Design

Details of the study have been published. Patients were aged ≥40 years, had provided written informed consent, had been hospitalized with ACS 1 to 12 months before randomization, and had LDL-C levels ≥70 mg/dL (1.81 mmol/L), or non–high-density lipoprotein cholesterol levels ≥100 mg/dL (2.59 mmol/L), or apolipoprotein B levels ≥80 mg/dL after ≥2 weeks of stable treatment with atorvastatin 40 to 80 mg daily, rosuvastatin 20 to 40 mg daily, or the maximum tolerated dose of one of these statins.

After a prerandomization run-in phase, patients were randomly assigned to blinded treatment with alirocumab 75 mg or matching placebo given by subcutaneous injection every 2 weeks (see Methods in the online-only Data Supplement). All patients provided written informed consent. All sites obtained institutional review board approval as per local and national guidelines.

Statistical Analysis

Efficacy was determined by time to first occurrence of any component of a given end point by intention-to-treat. Design assumptions were a primary end point incidence of 11.4% at 4 years in the placebo group and a median baseline LDL-C level of 90 mg/dL (2.33 mmol/L), reduced by 50% with alirocumab treatment, resulting in an expected 15% hazard reduction. At a 5% significance level, the trial had 90% power with 1613 primary end point events occurring in 18,000 patients with a median follow-up of approximately 3 years. In China, 614 patients were randomized after the main trial cohort. The protocol specified that the trial continue until at least 1613 primary end point events occurred and all evaluable patients had been followed for ≥2 years (except those from China), ensuring a minimum observation time to assess safety and efficacy. There were no study-powering assumptions around death. Treatment HRs and 95%
CIs were estimated by Cox proportional hazards models, stratified by geographic region; P values were determined by stratified log-rank tests. Heterogeneity of treatment effects in subgroups based on incidences in the absolute scale were compared with the Gail-Simon test.9

A prespecified analysis (outside of the hierarchical analysis of efficacy) evaluated treatment effect on death among patients eligible for ≥3 years of follow-up (ie, randomized ≥3 years before the common study end date) on an intention-to-treat basis. Another prespecified analysis determined whether treatment effect on death was different before and after 1 year of follow-up, by comparing Cox proportional hazard models that allowed the treatment HR to vary before and after 1 year (stratified by region) to models where the treatment HR was assumed constant over time, and was done to test whether the former or latter analysis provided a better fit to the observed data.

To explore the association between the risks of nonfatal cardiovascular events and cardiovascular or noncardiovascular death, hazard functions for total (first and subsequent) nonfatal cardiovascular events (myocardial infarction, stroke [including hemorrhagic], or unstable angina requiring hospitalization) and cardiovascular or noncardiovascular death were estimated by general joint semiparametric models.10

The model includes 2 independent association parameters that represent the strength of within-patient association between nonfatal event times and within-patient association of nonfatal and fatal event times. If the association parameter between nonfatal events is 0, nonfatal event times for a given patient are independent, whereas an association parameter >0 indicates association between nonfatal event times. Likewise, if the association parameter for nonfatal and fatal events is 0, nonfatal and fatal event times for a given patient are independent, whereas an association parameter >0 indicates that nonfatal and fatal event times are associated. Treatment effects on nonfatal and fatal events are summarized separately by HRs and corresponding 95% CIs. Point estimates and corresponding 95% CIs are also generated for association parameters. Additional details of the model are provided in the Methods in the online-only Data Supplement.

To determine the association between baseline LDL-C and death, patients were classified according to baseline levels of LDL-C in prespecified categories of <80 mg/dL (2.07 mmol/L), 80 to <100 mg/dL (2.07 to <2.59 mmol/L), and ≥100 mg/dL (2.59 mmol/L). To assess the relationship between LDL-C achieved on alirocumab at month 4 and the subsequent risk of death, a spline plot was created, with an HR of 1 set to the median value of achieved LDL-C in that treatment group. The latter analysis was performed post hoc and was adjusted for age, region, diabetes mellitus status, and baseline LDL-C.

RESULTS

A total of 18,924 patients were randomized at 1315 sites in 57 countries (see Figure in the Data Supplement). Median follow-up was 2.8 (interquartile range, 2.3–3.4) years. Premature treatment discontinuation for reasons other than death or blind switch to placebo because of low LDL-C levels occurred in 1343 (14.2%) patients receiving alirocumab and 1496 (15.8%) patients receiving placebo. Ascertainment for vital status was complete in 99.8% of potential patient-years of follow-up.

Effect on the Primary End Point

As previously reported,8 the primary end point occurred in 903 (9.5%) patients in the alirocumab group and 1052 (11.1%) patients in the placebo group, with 4-year Kaplan-Meier estimates of 12.5% and 14.5%, respectively (HR stratified by region, 0.85; 95% CI, 0.78 to 0.93; P<0.001). The effect of alirocumab was less pronounced during the first year (HR, 0.94; 95% CI, 0.83 to 1.08; P=0.38), and was greater after the first year (HR, 0.77; 95% CI, 0.69 to 0.87; P<0.001). A prespecified analysis showed that a model allowing the treatment effect to differ before and after the first year of follow-up fit the data better than a model with a constant treatment effect (P=0.03 for model fit improvement).

Effect on All-Cause Death

A total of 726 (3.8%) patients died during the trial. The baseline characteristics of the total cohort, survivors, and patients who died are summarized in Table I. Fewer deaths occurred in the alirocumab group versus the placebo group (334 [3.5%] vs 392 [4.1%], respectively; HR, 0.85; 95% CI, 0.73 to 0.98; P=0.0073; Figure 1). Because all-cause death followed CHD death and cardiovascular death in the prespecified hierarchy of main secondary end points, the P value for all-cause death was considered nominal. Based on Kaplan-Meier estimates of death at 4 years of 5.3% and 6.4%, respectively, in the alirocumab and placebo groups, the absolute risk reduction was 1.1%, and the number of patients needed to treat for 4 years to prevent 1 death was 87.

Similar to the primary end point, allowing a nonconstant treatment HR on all-cause death suggested a lag in the treatment effect of alirocumab; treatment benefit was absent during the first year (HR, 1.01; 95% CI, 0.77 to 1.32; P=0.95), but was evident after the first year (HR, 0.79; 95% CI, 0.66 to 0.94; P=0.0073; P=0.13 for improvement in model fit versus the constant hazard model [with an HR of 0.85]).

Given prior evidence for a delayed benefit of lipid lowering in many statin trials, a prespecified analysis examined whether lower mortality with alirocumab was related to the potential duration of treatment. We examined death among 8242 patients (44% of the full study cohort) eligible for ≥3 years of follow-up. The baseline characteristics of this subset and of patients enrolled for <3 years before the common study end date are described in Table I in the online-only Data Supplement. Among patients eligible for ≥3 years of follow-up, the benefit of alirocumab on all-cause death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01; Figure 2) appeared more pronounced than in the overall trial population.
Table 1. Baseline Characteristics

| Characteristic | All Patients (n=18,924)* | Died During Follow-Up (n=726)* | Alive at End of Follow-Up (n=18,198)* |
|----------------|--------------------------|---------------------------------|--------------------------------------|
| Age, y         | 59 (52–65)               | 64 (57–71)                      | 58 (52–65)                           |
| Female sex     | 4762 (25.2)              | 202 (27.8)                      | 4560 (25.1)                          |
| Race           |                          |                                 |                                      |
| White          | 15,024 (79.4)            | 551 (75.9)                      | 14,443 (79.5)                        |
| Asian          | 2498 (13.2)              | 93 (12.8)                       | 2405 (13.2)                          |
| Black or African American | 473 (2.5) | 26 (3.6)                      | 447 (2.5)                           |
| Other          | 929 (4.9)                | 56 (7.7)                        | 873 (4.8)                            |
| Region of enrollment |                    |                                 |                                      |
| Central and Eastern Europe | 5437 (28.7) | 234 (32.2)                      | 5203 (28.6)                          |
| Western Europe | 4175 (22.1)              | 84 (11.6)                       | 4091 (22.5)                          |
| Canada/USA     | 2871 (15.2)              | 136 (18.7)                      | 2735 (15.0)                          |
| Latin America  | 2588 (13.7)              | 133 (18.3)                      | 2455 (13.5)                          |
| Asia           | 2293 (12.1)              | 75 (10.3)                       | 2218 (12.2)                          |
| Rest of the world | 1560 (8.2)     | 64 (8.8)                        | 1496 (8.2)                           |
| Medical history before index ACS |            |                                 |                                      |
| Hypertension   | 12,249 (64.7)            | 583 (80.3)                      | 11,666 (64.1)                        |
| Family history of premature CHD | 6773 (35.8) | 272 (37.5)                      | 6501 (35.7)                          |
| Myocardial infarction | 3639 (19.2) | 245 (33.7)                      | 3394 (18.7)                          |
| PCI            | 3241 (17.1)              | 188 (25.9)                      | 3053 (16.8)                          |
| CABG           | 1047 (5.5)               | 98 (13.5)                       | 949 (5.2)                            |
| Stroke         | 611 (3.2)                | 68 (9.4)                        | 543 (3.0)                            |
| Peripheral artery disease | 759 (4.0)   | 76 (10.5)                       | 683 (3.8)                            |
| Congestive heart failure | 2815 (14.9) | 241 (33.2)                      | 2574 (14.1)                          |
| COPD           | 746 (3.9)                | 102 (14.0)                      | 644 (3.5)                            |
| Malignant disease | 532 (2.8)                | 35 (4.8)                        | 497 (2.7)                            |
| Diabetes status |                         |                                 |                                      |
| Diabetes mellitus | 5444 (28.8)            | 346 (47.7)                      | 5098 (28.0)                          |
| Prediabetes    | 8246 (43.6)              | 253 (34.8)                      | 7993 (43.9)                          |
| Normal         | 5234 (27.7)              | 127 (17.5)                      | 5107 (28.1)                          |
| Tobacco smoking status |            |                                 |                                      |
| Current        | 4560 (24.1)              | 164 (22.6)                      | 4396 (24.2)                          |
| Former         | 7811 (41.3)              | 311 (42.8)                      | 7500 (41.2)                          |
| Never          | 6552 (34.6)              | 251 (34.6)                      | 6301 (34.6)                          |
| Index ACS event |                          |                                 |                                      |
| STEMI          | 6536 (34.6)              | 181 (25.1)                      | 6355 (35.0)                          |
| Non-STEMI      | 9175 (48.6)              | 407 (56.5)                      | 8768 (48.2)                          |
| Unstable angina | 3182 (16.8)             | 132 (18.3)                      | 3050 (16.8)                          |
| PCI or CABG for index ACS | 13,677 (72.3) | 421 (58.0)                      | 13,256 (72.8)                        |
| Time from index ACS to randomization, months | 2.6 (1.7–4.3) | 2.5 (1.7–3.7)                      | 2.6 (1.7–4.4)                        |
| Body mass index | 27.9 (25.2–31.1)         | 27.7 (24.5–31.5)                | 27.9 (25.2–31.1)                     |

(Continued)

Table 1. Continued

| Characteristic | All Patients (n=18,924)* | Died During Follow-Up (n=726)* | Alive at End of Follow-Up (n=18,198)* |
|----------------|--------------------------|---------------------------------|--------------------------------------|
| Lipid levels at randomization, mg/dL§ |            |                                 |                                      |
| LDL-C          | 86 (73–104)              | 91 (74–110)                     | 86 (73–104)                          |
| Non-HDL-C      | 115 (99–137)             | 120 (100–143)                   | 115 (99–136)                         |
| Apolipoprotein B | 79 (69–93)               | 82 (71–98)                      | 79 (69–93)                           |
| HDL-C          | 43 (36–50)               | 42 (36–51)                      | 43 (36–50)                           |
| Triglycerides  | 129 (94–182)             | 132 (92–187)                    | 129 (94–182)                         |
| Lipoprotein(a) | 21 (7–60)                | 22 (7–57)                       | 21 (7–60)                            |
| Hemoglobin A1c % | 5.8 (5.5–6.3)            | 6.1 (5.5–6.3)                   | 5.8 (5.5–6.3)                        |
| Glomerular filtration rate, ml/min per 1.73 m² | 78.2 (67.4–90.1) | 70.2 (54.9–85.2)                | 78.5 (67.8–90.4)                     |
| High-sensitivity C-reactive protein, mg/L | 1.6 (0.8–3.9) | 2.8 (1.1–6.6)                      | 1.6 (0.8–3.8)                        |

ACE indicates angiotensin converting enzyme; ACS, acute coronary syndrome; ARB, angiotensin II receptor blocker; CABG, coronary artery bypass graft; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PCI, percutaneous coronary intervention; and STEMI, ST-segment-elevation myocardial infarction.

§Data are expressed as median (interquartile range) or No. (%).

$Calculated as weight in kilograms divided by the square of the height in meters.

To convert the values for cholesterol to mmol/L, multiply by 0.02586. To convert the values for triglycerides to mmol/L, multiply by 0.01129.

ILDL-C was calculated with the Friedewald formula; calculated values <15 mg/dL were confirmed by ultracentrifugation/beta quantification.

For patients eligible for <3 years of follow-up, the treatment HR for all-cause death was 0.96 (95% CI, 0.76 to 1.21; P=0.71; interaction P=0.19).

**Effect on Cardiovascular and Noncardiovascular Death**

As previously reported, CVD death occurred in 240 (2.5%) patients in the alirocumab group and 271
(2.9%) patients in the placebo group (HR, 0.88; 95% CI, 0.74 to 1.05; \( P = 0.15 \)), and represented 511 (70.4%) of all-cause deaths. Noncardiovascular death was also numerically lower with alirocumab (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; \( P = 0.06; \) Figure 1). Adjudicated cardiovascular and noncardiovascular causes of death are summarized in Tables II and III in the online-only Data Supplement. There was a low proportion of undetermined causes of death. Among 31 fewer cardiovascular deaths in the alirocumab group than in the placebo group, the largest differences between groups were for fatal myocardial infarction (n=10) and sudden cardiac death (n=8). Among 27 fewer noncardiovascular causes of death in the alirocumab group versus the placebo group, the largest difference was for death by pulmonary (n=14) causes.

### Relationship Between Nonfatal Cardiovascular Events and Cardiovascular or Noncardiovascular Death

Overall, there were 206 fewer nonfatal cardiovascular events in the alirocumab group than in the placebo group. When nonfatal cardiovascular events and cardiovascular or noncardiovascular death are described as ordinal functions (Table 2), there were numerically fewer of all types of events with alirocumab than with placebo as first events, second events, and third or more events, suggesting a linkage between the nonfatal events and cause-specific death.

Furthermore, successive nonfatal cardiovascular events were associated with a progressively greater risk of subsequent cardiovascular and noncardiovascular deaths. Among patients at risk for a first event in the alirocumab and placebo groups, noncardiovascular
death occurred as a first event in 0.8% and 0.9%, while cardiovascular death occurred as a first event in 1.7% and 1.8%, respectively. After a first nonfatal cardiovascular event occurring an overall median of 1.1 (0.4, 1.9) years after randomization, noncardiovascular death occurred as a second event in 1.8% and 2.0%, while cardiovascular death occurred as a second event in 7.9% and 8.0%, respectively, of the patients in the alirocumab and placebo groups. Similarly, after a second nonfatal cardiovascular event occurring an overall median of 1.5 (0.9, 2.3) years after randomization, noncardiovascular death subsequently occurred in 3.7% and 6.2%, while cardiovascular death subsequently occurred in 11.1% and 14.8%, respectively, of the patients in the alirocumab and placebo groups. Qualitatively, these data indicate that each successive prior nonfatal cardiovascular event is associated with an increased subsequent risk for both cardiovascular and noncardiovascular death, and that the rate of subsequent cardiovascular death is four times higher than the rate of subsequent noncardiovascular death.

To provide a quantitative exploration of an association between nonfatal cardiovascular events and cardiovascular death, general joint semiparametric models were constructed for cause-specific death and nonfatal cardiovascular events with treatment assignment in the hazard functions. When the fatal event was noncardiovascular death (see Table IV in the online-only Data Supplement), alirocumab reduced total nonfatal cardiovascular events (HR, 0.82; 95% CI, 0.74 to 0.91; P=0.0002) and was a predictor of reduced noncardiovascular mortality (P=0.052). The association parameter between nonfatal cardiovascular events and noncardiovascular death of 2.35 (95% CI, 1.98 to 2.73) indicates patients at higher risk for noncardiovascular death were also at higher risk for nonfatal cardiovascular events (P<0.0001). Thus, a dependency between antecedent nonfatal cardiovascular events and subsequent noncardiovascular death, coupled with a reduction in the former with alirocumab (described in the primary analysis of the trial8 and in Table V in the online-only Data Supplement), indicates that prevention of nonfatal cardiovascular events may have contributed to the lower number of noncardiovascular deaths with alirocumab.

There was a similar strong dependency between antecedent nonfatal cardiovascular events and subsequent cardiovascular death (see Table VI in the online-only Data Supplement), with association parameter 3.49 (95% CI, 3.03 to 3.95; P<0.0001).

To explore whether the strength of the relationship between nonfatal cardiovascular events and noncardiovascular death was affected by adjustment for factors that were prognostic for one or both of nonfatal cardiovascular events or noncardiovascular death, a multivariable general joint semiparametric model was fit with 13 baseline patient characteristics expected to be predictive of these events (see Methods in the online-only Data Supplement). The resulting association parameter between nonfatal and fatal events of 1.03 (95% CI, 0.77 to 1.28) remained significant (P<0.0001), indicating a persistent, strong relationship between nonfatal cardiovascular events and noncardiovascular death.

### Table 2. Number and Timing of Cases of Cardiovascular or Noncardiovascular Death and Nonfatal Myocardial Infarction, Stroke, or Unstable Angina Requiring Hospitalization According to Ordinal Event Number

|                      | Alirocumab | Placebo |
|----------------------|------------|---------|
|                      | No. (%)    | Median (IQR) Event Time* | No. (%)    | Median (IQR) Event Time* |
| **First event**      |            |                     |            |                     |
| Nonfatal myocardial infarction, stroke, or unstable angina | 761/9462 (8.0) | 1.0 (0.4–1.9) | 917/9462 (9.7) | 1.1 (0.5–1.9) |
| Cardiovascular death  | 162/9462 (1.7) | 1.3 (0.6–2.2) | 167/9462 (1.8) | 1.5 (0.7–2.3) |
| Noncardiovascular death | 74/9462 (0.8) | 1.9 (1.2–2.5) | 90/9462 (0.9) | 1.8 (1.2–2.4) |
| **Second event**     |            |                     |            |                     |
| Nonfatal myocardial infarction, stroke, or unstable angina | 162/761 (21.3) | 1.4 (0.9–2.2) | 210/917 (22.9) | 1.6 (0.9–2.4) |
| Cardiovascular death  | 60/761 (7.9) | 1.3 (0.7–2.4) | 73/917 (8.0) | 1.5 (0.8–2.4) |
| Noncardiovascular death | 14/761 (1.8) | 2.7 (1.8–3.3) | 18/917 (2.0) | 1.6 (1.1–2.4) |
| **Third or more event(s)** |            |                     |            |                     |
| Nonfatal myocardial infarction, stroke, or unstable angina | 111 |                     | 113 |                     |
| Cardiovascular death  | 18/162 (11.1) |                     | 31/210 (14.8) |                     |
| Noncardiovascular death | 6/162 (3.7) |                     | 13/210 (6.2) |                     |
| Total cardiovascular deaths | 240/9462 (2.5) | 1.3 (0.6–2.2) | 271/9462 (2.9) | 1.6 (0.8–2.4) |
| Total noncardiovascular deaths | 94/9462 (1.0) | 2.0 (1.4–2.7) | 121/9462 (1.3) | 1.8 (1.2–2.4) |

IQR indicates interquartile range.

*Event time is expressed as years since randomization.
Relationship of Death to Baseline and Achieved LDL-C Levels

In a post hoc analysis, death was examined in three predefined subgroups of baseline LDL-C level (<80 mg/dL [2.07 mmol/L], 80 to <100 mg/dL [2.07 to <2.59 mmol/L], and ≥100 mg/dL [2.59 mmol/L]; Figure 3). The HR for death was numerically lowest in the subgroup with baseline LDL-C ≥100 mg/dL (0.71; 95% CI, 0.56 to 0.90), but there was no significant heterogeneity of the effect of alirocumab on relative risk of death across categories of baseline LDL-C ($P_{\text{interaction}}=0.12$). In contrast, there were significant gradients of the absolute risk of death in the placebo group and the absolute difference in death between alirocumab and placebo groups across baseline LDL-C subgroups, with greatest risk in the placebo group and greatest absolute risk reduction with alirocumab in the subgroup with baseline LDL-C ≥100 mg/dL ($P_{\text{interaction}}<0.005$). Using the Kaplan-Meier estimates of all-cause death at 4 years for patients with a baseline LDL-C value ≥100 mg/dL (5.8% vs 9.6%), the absolute risk reduction was 3.8%, and the number needed to treat for 4 years to avoid 1 death in that patient subset was 26.

Spline analysis related continuous values of achieved LDL-C at 4 months to the subsequent risk of death. In the alirocumab group (median achieved LDL-C, 31 mg/dL), the risk of death declined with lower achieved LDL-C, down to an LDL-C level of approximately 30 mg/dL (adjusted $P$ value for model = 0.017 for linear trend) (Figure 4).

DISCUSSION

In ODYSSEY OUTCOMES, alirocumab, when added to intensive statin treatment, was associated with fewer all-cause deaths than placebo in patients with recent ACS and elevated atherogenic lipoproteins. This finding is considered nominally significant based on the prespecified hierarchical analysis of secondary end points. In an additional prespecified analysis, the treatment effect on death was particularly prominent among patients with a potential follow-up of ≥3 years. Patients starting at a higher baseline LDL-C level had a particularly prominent reduction in death with alirocumab, and patients achieving lower LDL-C levels at 4 months of treatment with alirocumab experienced a reduced risk of death.

A lower mortality was observed with alirocumab in the ODYSSEY OUTCOMES trial, whereas no difference in death was found with evolocumab or bococizumab, compared with placebo, in the FOURIER and SPIRE trials. This may be because of differences in the drugs and in the trial populations: the different findings in ODYSSEY OUTCOMES versus the FOURIER and SPIRE trials may be related to a population of patients with recent ACS in the former, whereas FOURIER enrolled stable patients with established atherosclerotic cardiovascular disease, and SPIRE enrolled a mixture of patients at high cardiovascular risk or with a previous cardiovascular event. Another possible explanation for different mortality findings is the duration of follow-up, which was longer in ODYSSEY OUTCOMES (median, 2.8 years) than in FOURIER (2.2 years) or SPIRE-2 (12 months). Notably, ODYSSEY OUTCOMES had 8242 patients eligible for ≥3 years of follow-up, with some patients followed for as long as 5 years. In ODYSSEY OUTCOMES, a stronger treatment effect was seen beyond year 1 (albeit statistically significantly for only the primary outcome). These observations suggest that longer treatment with alirocumab resulted in greater clinical...
benefit that was eventually discerned as a reduction in death.

Supporting the mortality reduction with alirocumab is the observation that patients in the highest predefined category of baseline LDL-C (≥100 mg/dL [2.59 mmol/L]) not only were at the highest absolute risk for major adverse cardiovascular events or death (as demonstrated by the event rates in the placebo arm), but also achieved the greatest absolute treatment benefit on major adverse cardiovascular events and death with alirocumab. Importantly, this subset of patients is one that would have been predicted to derive a mortality benefit based upon meta-analysis of previous lipid-lowering trials that demonstrated the greatest reductions in total and cardiovascular deaths in patients with high baseline LDL-C levels, particularly those with baseline LDL-C ≥100 mg/dL.

An important observation in this report is that fewer all-cause deaths with alirocumab resulted from numerically fewer noncardiovascular as well as cardiovascular deaths. While the latter effect has an obvious mechanistic linkage to lipid lowering, the former effect may be less intuitive. It may appear to run counter to the concept of competing mortality risks, whereby a reduction in total and cardiovascular deaths in patients with high baseline LDL-C levels, particularly those with baseline LDL-C ≥100 mg/dL.

There are some limitations to our analysis. First, the classification of deaths as cardiovascular or noncardiovascular is unavoidably imperfect. Thus, total mortality may be a more reliable indicator of efficacy in long-term cardiovascular outcomes trials, and many deaths of unknown cause may in fact be cardiovascular. Indeed, in the Cholesterol Treatment Trialist Collaborative meta-analysis of 26 randomized statin trials, there were numerically fewer deaths of unknown cause with statins than with placebo (HR, 0.87; 95% CI, 0.73 to 1.03). In addition, the larger number of total deaths than either cardiovascular (~70% of total) or noncardiovascular deaths (~30% of total) provides more power to discern an effect on death from any cause. Second, the ODYSSEY OUTCOMES trial was designed to test a treat-to-target approach to lowering LDL-C levels after ACS. We cannot determine the extent, if any, to which intentional avoidance of very low LDL-C levels with a blinded dose-titration scheme influenced the mortality findings in the trial. Third, the mortality reduction with alirocumab is considered nominal given the position of all-cause death after end points that were not significantly reduced in the prespecified hierarchy of efficacy end points. Fourth, there are no head-to-head comparisons of the effects of PCSK9 inhibitors on clinical outcomes, and thus there are no data to prove that one agent is more effective than another on any specific clinical outcome or in any specific type of patient. Differences among trials with PCSK9 inhibitors regarding outcomes including death may be caused by differences in trial design (eg, duration of follow-up). Finally, as in any cardiovascular events, alirocumab had a strong favorable effect on the latter. Thus, the reduction in nonfatal cardiovascular events with alirocumab may have contributed to effects on both noncardiovascular and cardiovascular death, and in turn on all-cause death. Clinically, the prevention of nonfatal cardiovascular events may prevent cumulative disability, frailty, and susceptibility to the mechanisms of noncardiovascular illness and death. In that respect, the majority of the difference in noncardiovascular deaths between groups (27 deaths) was related to a reduction in pulmonary deaths (14 fewer with alirocumab; see Table III in the online-only Data Supplement).

Finally, a greater effect of alirocumab to reduce death was associated both with higher baseline LDL-C and with lower on-treatment levels of LDL-C, as previously observed in statin trials. This finding suggests that patients with ACS who fail to achieve adequate reduction of LDL-C on conventional lipid-lowering therapy, particularly those whose LDL-C levels remain ≥100 mg/dL, may achieve a survival benefit with alirocumab treatment. Moreover, patients in the alirocumab group had a significant graded relationship of achieved LDL-C level to subsequent mortality, apparent to an achieved LDL-C level of approximately 30 mg/dL.

Figure 4. All-cause death spline analysis of continuous intention-to-treat month-4 LDL-C for alirocumab-treated patients.

*Hazard ratio (dashed lines indicate upper and lower bounds of the 95% confidence interval) is relative to median month-4 LDL-C (31 mg/dL [0.80 mmol/L]), adjusted for age, sex, geographic region, diabetes status, and baseline LDL-C. Degree = 3, 3 knots located at month-4 LDL-C quartiles (0.52, 0.80, and 1.27 mmol/L [20, 31, and 49 mg/dL]), $P$ value for month 4 spline effect = 0.0169. LDL-C indicates low-density lipoprotein cholesterol.
clinical trial, the effects observed in carefully selected participants may not fully reflect those that may be observed when the treatment is applied in a broader, less selective population treated in routine clinical practice.

CONCLUSIONS
This report provides evidence that alirocumab, added to intensive statin treatment, may reduce all-cause death after ACS in patients with elevated atherogenic lipoproteins. Greater treatment benefit occurs beyond the first year, in patients with longer follow-up, and in patients with higher baseline LDL-C values ≥100 mg/dL. Patients achieving lower LDL-C values at 4 months, down to approximately 30 mg/dL, appear to be at lower risk of subsequent death. The findings indicate that long-term treatment with alirocumab in appropriately selected patients may result in prolongation of life.

ARTICLE INFORMATION
Received November 11, 2018; accepted April 24, 2019.

The online-only Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.038840.

Authors
Philippe Gabriel Steg, MD*; Michael Szarek, PhD; Deepak L. Bhatt, MD, MPH; Vera A. Bittner, MD, MSPH; Marie-France Brégault, MD; Antonio J. Dalby, MD; Rafael Diaz, MD; Jay M. Edelberg, MD; Shaun G. Goodman, MD; MSc; Corinne Hanotin, MD; Robert A. Harrington, MD; J. Wouter Jukema, MD; Anthony J. Kabrhel, MD; Guillaume Lecorps, MSc; Kenneth W. Mahaffey, MD; Angelo Monyusef, PhD; Petr Ostadal, MD, PhD; Alexander Parkhomenko, MD; Robert Pordy, MD; Matthew T. Roe, MD, MHS; Pierluigi Tricoci, MD, PhD; Robert Vogel, MD; Harvey D. White, DSc; Andreas M. Zeiher, MD; Gregory G. Schwartz, MD, PhD*; For the ODYSSEY OUTCOMES Committees and Investigators*; Sophie Rushton-Smith, PhD (MedLink Healthcare Communications, Tarrytown, NY (R.P.)). Duke Clinical Research Institute, Duke University Medical Center, New York (H.D.W.). Department of Medicine III, Goethe University, Frankfurt am Main, Germany (A.M.Z.). Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.).

Acknowledgments
We thank the patients, study coordinators, and investigators who participated in this trial. Sophie Rushotn-Smith, PhD (MedLink Healthcare Communications, London), provided editorial assistance in the preparation of the manuscript (limited to editing for style, referencing, and figure and table editing) and was funded by Fondation Assistance Publique–Hôpitaux de Paris, France.

The protocol and statistical analysis plan were conceived by the first three authors, developed in conjunction with the other members of the executive steering committee and sponsors, and approved by responsible regulatory authorities and ethics committees. The sponsors participated in study site selection, monitoring, and supervision of data collection. Duke Clinical Research Institute led blinded end point adjudication. An independent data monitoring committee monitored safety and efficacy data. Analyses were performed independently by the academic statistician in parallel with the sponsors. The manuscript was drafted by the first author with input from all authors. The executive steering committee decided to publish the paper and takes responsibility for the completeness and accuracy of the data and the fidelity of the trial to the protocol.

The first author had full access to the data in the study, takes responsibility for the integrity of the data and the accuracy of the data analysis, and had full responsibility for the decision to submit for publication.

Additional author contributions are as follows: Concept and design: P.G.S., M.S., D.L.B., V.A.B., R.D., S.G.G., R.A.H., J.W.J., K.W.M., M.T.R., H.D.W., A.M.Z., G.G.S. Acquisition of the data: P.G.S., M.S., D.L.B., V.A.B., A.J.D., R.D., S.G.G., R.A.H., J.W.J., K.W.M., P.O., A.M.T., R.V., H.D.W., A.M.Z., G.G.S. Analysis or interpretation of the data: P.G.S., M.S., G.L., P.L.T., G.G.S. Drafting of the manuscript: P.G.S. Critical revision of the manuscript: all. Statistical analysis: M.S., G.L. Obtained funding: P.G.S., G.G.S. Administrative, technical or material support: M.F.B., J.M.E., A.M., R.P. Supervision: P.G.S. and G.G.S.

Sources of Funding
The trial was funded by Sanofi and Regeneron Pharmaceuticals, Inc.

Disclosures
Dr Steg: research grants from Bayer, Merck, Sanofi, and Servier; speaking or consulting fees from Amarin, Amgen, AstraZeneca, Bayer/Lijanssen, Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Inc, Sanofi, and Servier. Dr Szarek: consultant/advisory board for CiVi, Resverlogix, Baxter, and Regeneron Pharmaceuticals, Inc. Dr Bhatt: advisory board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, Regeneron Pharmaceuticals, Inc. Dr Bhatt: advisory board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, Regeneron Pharmaceuticals, Inc. Dr Bhatt: advisory board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, Regeneron Pharmaceuticals, Inc.

Downloaded from http://ahajournals.org by on November 28, 2019
REFERENCES

1. Robinson JG, Farnier M, Kremef M, Bergeron J, Luc G, Avina M, Stroes ES, Langint G, Raal FJ, El Shawawy M, Keron MJ, Lepor NE, Lorenzo C, Pondy R, Chaudhuri U, Kastelen JF, ODYSSEY LONG TERM Investigators. Safety and efficacy of alirocumab in reducing lipids and cardiovascular events: a 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370:1809–1819. doi: 10.1056/NEJMoa1316222

2. Sabatine MS, Giugliano RP, Wiviott SD, Jaff J, Blom DJ, Robinson J, Ballantyne CM, Somarate R, Legg J, Wasserman SM, Scott R, Koonen MJ, Stein EA; OSLER Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1500–1509. doi: 10.1056/NEJMoa1500858

3. Blom D, Hala T, Bolognesi M, Lillesdiv ML, Thot PD, Burgess L, Ceska R, Roth E, Koonen MJ, Ballantyne CM, Monsolvo ML, Tirtsonik K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2013;370:1809–1819. doi: 10.1056/NEJMoa1316222

4. Sabatine MS, Giugliano RP, Kech AC, Honapour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1722–1722. doi: 10.1056/NEJMoa1615664

5. Rickard PM, Revkin J, Amarencio P, Brunell R, Curto M, Civeira F, Flather M, Gunnell G, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lennartz M, Mange P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nolus N, Poskivcik P, Santos RD, Scharf P, Saran H, White H, Wright R, Ybarb M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376:1527–1539. doi: 10.1056/NEJMoa1701488

6. Schwartz GG, Bessac L, Berland DG, Bhatt DL, Bittner VD, Draz R, Goodman SG, Hansotin C, Harrington RA, Jukema JW, Mahaffey KW, Morysuef A, Perry R, Roe MR, Toth PD, Haciara W, Shirodaria C, Szarek M, Tamby J, Tricoci P, Wei H, Zeisler AM, Stieglitz AG; ODYSSEY OUTCOmmes Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168:682–690. doi: 10.1016/j.ahj.2014.07.028

7. Schwartz GG, Bessac L, Berland DG, Bhatt DL, Bittner VD, Draz R, Goodman SG, Hansotin C, Harrington RA, Jukema JW, Mahaffey KW, Morysuef A, Perry R, Roe MR, Toth PD, Haciara W, Shirodaria C, Szarek M, Tamby J, Tricoci P, Wei H, Zeisler AM, Stieglitz AG; ODYSSEY OUTCOmmes Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–2107. doi: 10.1056/NEJMoa1811174

8. Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subgroups. Biometrics. 1985;41:361–372.

9. Rondeaux V, Mathoulin-Pelissier S, Jacqmin-Gadda H, Brouss V, Soubeyran P. Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events. Biostatistics. 2007;8:708–721. doi: 10.1093/biostatistics/kxl043

10. Navarese EP, Robinson JG, Kwakalewski M, Kozludzieczak M, Andreotti F, Bulden T, Tardif JC, Brouss V, Soubeyran P, Riewand H. Long-term follow-up of ALIPI and ODYSSEY outcomes trial. J Am Heart Assoc. 2019;7:100–107. doi: 10.1161/JAHA.118.008580

11. Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chen CE, Draz R, Edwards J, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Morysuef A, Perry R, Roe MR, Toth PD, Haciara W, Shirodaria C, Szarek M, Tamby J, Tricoci P, Wei H, Zeisler AM, Stieglitz AG; ODYSSEY OUTCOMES Com- mittees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. J Am Heart Assoc. 2018;7:207–210. doi: 10.1161/JAHA.118.008580

12. Fanaroff AC, Roe MT, Clare RM, Lokhnygina Y, Navar AM, Giugliano RP, Blom DJ, Hala T, Bolognesi M, Lillesdiv ML, Thot PD, Burgess L, Ceska R, Roth E, Koonen MJ, Ballantyne CM, Monsolvo ML, Tirtsonik K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2013;370:1809–1819. doi: 10.1056/NEJMoa1316222

13. Schwartz GG, Bessac L, Berland DG, Bhatt DL, Bittner VD, Draz R, Goodman SG, Hansotin C, Harrington RA, Jukema JW, Mahaffey KW, Morysuef A, Perry R, Roe MR, Toth PD, Haciara W, Shirodaria C, Szarek M, Tamby J, Tricoci P, Wei H, Zeisler AM, Stieglitz AG; ODYSSEY OUTCOmmes Investigators. Alirocumab reduces total nonfatal cardiovascular events following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014;168:682–689. doi: 10.1016/j.ahj.2014.07.028

14. Fanaroff AC, Roe MT, Clare RM, Lokhnygina Y, Navar AM, Giugliano RP, Blom DJ, Hala T, Bolognesi M, Lillesdiv ML, Thot PD, Burgess L, Ceska R, Roth E, Koonen MJ, Ballantyne CM, Monsolvo ML, Tirtsonik K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2013;370:1809–1819. doi: 10.1056/NEJMoa1316222

15. Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, Chen CE, Draz R, Edwards J, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Morysuef A, Perry R, Roe MR, Toth PD, Haciara W, Shirodaria C, Szarek M, Tamby J, Tricoci P, Wei H, Zeisler AM, Stieglitz AG; ODYSSEY OUTCOMES Com- mittees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. J Am Heart Assoc. 2018;7:100–107. doi: 10.1161/JAHA.118.008580